Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 1;16(11):2816-2821.
doi: 10.1080/21645515.2020.1741997. Epub 2020 Apr 3.

Review of long term immunogenicity and tolerability of live hepatitis A vaccine

Nitin Shah  1 , Mma Faridi  2 , Monjori Mitra  3 , Ashish Bavdekar  4 , Archana Karadkhele  5 , Gaurav Puppalwar  5 , Rishi Jain  5
Affiliations
Review

Review of long term immunogenicity and tolerability of live hepatitis A vaccine

Nitin Shah et al. Hum Vaccin Immunother. .

Abstract

Hepatitis A represents one of the major public health problems worldwide including India. Vaccination is the most effective way to prevent hepatitis A infection. Two types of hepatitis A vaccines-live attenuated (H2 strain) and inactivated (killed) are available for use in clinical practice in India with former having advantage of a single-dose compared to two-dose killed vaccine. One of the important characteristic of an ideal vaccine includes its ability to provide life-long protection. In this article we reviewed the available long-term (≥10 years follow-up) published data on live attenuated hepatitis A (H2 strain) vaccine. The data from country of origin of the vaccine (China) and India establish the long-term immunogenicity, protection, and tolerability. Based on the results of several clinical trials showing long-term protection, single dose of live attenuated hepatitis vaccine can be widely used to protect high-risk population against hepatitis A virus infection and related complications.

Keywords: hepatitis A vaccine; immunogenicity; live attenuated; tolerability.

PubMed Disclaimer

References

    1. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L.. Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol. 2012;4:68–73. doi:10.4254/wjh.v4.i3.68. - DOI - PMC - PubMed
    1. Hepatitis A questions and answers for the public CDC; [accessed 2019 September20]. https://www.cdc.gov/hepatitis/hav/afaq.htm
    1. Gossner CM, Severi E, Danielsson N, Hutin Y, Coulombier D. Changing hepatitis A epidemiology in the European Union: new challenges and opportunities. Euro Surveill. 2015;20(16):21101. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21101. - PubMed
    1. Arankalle V, Mitra M, Bhave S, Ghosh A, Balasubramanian S, Chatterjee S, Choudhury J, Chitkara A, Kadhe G, Mane A, et al. Changing epidemiology of hepatitis Avirus in Indian children. Vaccine. 2014;4:7–13.
    1. Hepatitis A vaccines – july 2012 WHO position paper; [accessed 2019 September20]. https://www.who.int/immunization/position_papers/PP_hep_A_july2012_summa....